Search Results

You are looking at 41 - 50 of 431 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced-Stage or Recurrent Endometrioid Endometrial

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced or Recurrent Endometrioid Endometrial

Full access

Harold J. Burstein

regimens dramatically. In fact, you only need 1: AC (doxorubicin/cyclophosphamide) followed by paclitaxel. Here is the following evidence. The Oxford overview, based on treatment of over 100,000 women in adjuvant trials, suggests that all women who need

Full access

Augustine Lau, Jessy Delaisla, Jeff Dang, Sang Chau, and Andrew Hertler

control group. For those with advanced squamous NSCLC, the addition of pembrolizumab to paclitaxel/nab-paclitaxel with carboplatin provided a 6.4 months PFS advantage versus 4.8 months in the control group. Methods: The sample was obtained from a

Full access

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced

Full access

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in

Full access

Armstrong, MD • 919-668-8108 ClinicalTrials.gov Identifier: NCT00887640 Weekly Nanoparticle Albumin-Bound Paclitaxel Plus Weekly Cetuximab Plus Radiation Therapy in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma Principal

Full access

Joyce Liu and Ursula Matulonis

. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996 ; 334 : 1 – 6 . 3. Ozols RF Bundy BN Greer BE . Phase III trial of carboplatin and paclitaxel compared

Full access

advanced melanoma Contact: Roswell Park Cancer Institute • 877-275-7724 • AskRPCI@roswellpark.org ClinicalTrials.gov Identifier: NCT01533948 Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies

Full access

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA